Anfarm Hellas S.A. - Main Component
Active Substance | Strength | Form |
---|---|---|
TeicoplaninUnder Development | 200 mg & 400 mg/vial | Pd.Sol.Inf |
Tenoxicam | 20mg/Vial | Ps.Inj.Sol |
Tenoxicam | 20mg | F.C.Tab |
Tigecycline | 50mg/Vial | Pd.Sol.Inf |
Active Substance | Strength | Form |
---|---|---|
TeicoplaninUnder Development | 200 mg & 400 mg/vial | Pd.Sol.Inf |
Tenoxicam | 20mg/Vial | Ps.Inj.Sol |
Tenoxicam | 20mg | F.C.Tab |
Tigecycline | 50mg/Vial | Pd.Sol.Inf |
Active Substance | Strength | Form | Market Availability |
---|---|---|---|
TeicoplaninUnder Development | 200 mg & 400 mg/vial | Pd.Sol.Inf | Q1 2023 |
Tenoxicam | 20mg/Vial | Ps.Inj.Sol | International |
Tenoxicam | 20mg | F.C.Tab | Selected Markets |
Tigecycline | 50mg/Vial | Pd.Sol.Inf | International |